CY1113561T1 - (2s,3r)-ν-(2-((3-πυριδινυλ)μεθυλ)-1-αζαδικυκλο[2.2.2]οκτ-3-υλ)βενζοφουραν-2-καρβοξαμιδιο, νεες μορφες αλατων και μεθοδοι χρησεως αυτων - Google Patents
(2s,3r)-ν-(2-((3-πυριδινυλ)μεθυλ)-1-αζαδικυκλο[2.2.2]οκτ-3-υλ)βενζοφουραν-2-καρβοξαμιδιο, νεες μορφες αλατων και μεθοδοι χρησεως αυτωνInfo
- Publication number
- CY1113561T1 CY1113561T1 CY20131100081T CY131100081T CY1113561T1 CY 1113561 T1 CY1113561 T1 CY 1113561T1 CY 20131100081 T CY20131100081 T CY 20131100081T CY 131100081 T CY131100081 T CY 131100081T CY 1113561 T1 CY1113561 T1 CY 1113561T1
- Authority
- CY
- Cyprus
- Prior art keywords
- salts
- benzofuran
- pyridinyl
- carboxamide
- oct
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- -1 (3-PYRIDINYL) Methyl Chemical group 0.000 title 2
- QHKJIJXBJCOABP-UHFFFAOYSA-N 1-benzofuran-2-carboxamide Chemical compound C1=CC=C2OC(C(=O)N)=CC2=C1 QHKJIJXBJCOABP-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 231100000877 autonomic nervous system dysfunction Toxicity 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- OXKRFEWMSWPKKV-GHTZIAJQSA-N n-[(2s,3r)-2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]-1-benzofuran-2-carboxamide Chemical compound C([C@@H]1N2CCC(CC2)[C@H]1NC(=O)C=1OC2=CC=CC=C2C=1)C1=CC=CN=C1 OXKRFEWMSWPKKV-GHTZIAJQSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95361307P | 2007-08-02 | 2007-08-02 | |
| US95361407P | 2007-08-02 | 2007-08-02 | |
| US95361007P | 2007-08-02 | 2007-08-02 | |
| US97165407P | 2007-09-12 | 2007-09-12 | |
| EP08782584A EP2182949B1 (en) | 2007-08-02 | 2008-08-01 | (2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1113561T1 true CY1113561T1 (el) | 2016-06-22 |
Family
ID=39945177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20131100081T CY1113561T1 (el) | 2007-08-02 | 2013-01-30 | (2s,3r)-ν-(2-((3-πυριδινυλ)μεθυλ)-1-αζαδικυκλο[2.2.2]οκτ-3-υλ)βενζοφουραν-2-καρβοξαμιδιο, νεες μορφες αλατων και μεθοδοι χρησεως αυτων |
Country Status (35)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| US8314119B2 (en) * | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| SA08290475B1 (ar) * | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| US20110098312A1 (en) * | 2008-05-12 | 2011-04-28 | Targacept ,Inc | Methods for preventing the development of retinopathy by the oral administration of nnr ligands |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
| CN103221411B (zh) | 2010-05-17 | 2016-05-11 | 富瑞姆制药公司 | (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型 |
| US20130225560A1 (en) * | 2010-07-26 | 2013-08-29 | Envivo Pharmaceuticals, Inc. | Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Acetylcholinesterase Inhibitors |
| CN106074548A (zh) | 2010-09-23 | 2016-11-09 | 艾伯维巴哈马有限公司 | 氮杂金刚烷衍生物的一水合物 |
| JP2014502996A (ja) * | 2011-01-18 | 2014-02-06 | ターガセプト，インコーポレイテッド | 統合失調症における認知障害の治療 |
| MX2013008704A (es) | 2011-01-27 | 2013-08-21 | Novartis Ag | Uso de activadores del receptor de acetil-colina nicotinico alfa-7. |
| PL2685979T3 (pl) | 2011-03-18 | 2017-02-28 | Alkermes Pharma Ireland Limited | Kompozycje farmaceutyczne do wstrzykiwania zawierające środek nierozpuszczalny w wodzie, środek przeciwpsychotyczny, laurynian sorbitanu i polisorbat 20 |
| MX2013010698A (es) | 2011-03-18 | 2014-02-17 | Novartis Ag | Combinaciones de activadores del receptor de acetil-colina nicotinico alfa-7 y antagonistas del receptor de glutamato metabotropico 5 (mglur5) para usarse en la discinesia inducida por dopamina en la enfermedad de parkinson. |
| WO2012129262A1 (en) | 2011-03-23 | 2012-09-27 | Targacept, Inc. | Treatment of attention deficit/hyperactivity disease |
| EP2727604A4 (en) | 2011-06-30 | 2015-03-18 | Toray Industries | ANTIPRURIGINOUS AGENT |
| TW201311698A (zh) * | 2011-08-22 | 2013-03-16 | Targacept Inc | 作為神經元菸鹼乙醯膽鹼受體配位體之１，４－二氮雜雙環［３．２．２］壬烷 |
| CA3083244C (en) | 2011-10-20 | 2023-01-03 | Novartis Ag | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment |
| US9993556B2 (en) * | 2012-03-19 | 2018-06-12 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty glycerol esters |
| AU2013235519C1 (en) | 2012-03-19 | 2018-04-26 | Alkermes Pharma Ireland Limited | Pharmaaceutical compositions comprising fatty acid esters |
| CA2867137C (en) | 2012-03-19 | 2020-12-08 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol |
| AU2013259871A1 (en) | 2012-05-08 | 2014-11-20 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
| NZ730571A (en) | 2012-09-19 | 2018-12-21 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions having improved storage stability |
| JP6114951B2 (ja) | 2012-12-11 | 2017-04-19 | ノバルティス アーゲー | アルファ７ニコチン性アセチルコリン受容体アクチベーターによる処置に対する応答性を予測するバイオマーカー |
| US20150313884A1 (en) | 2013-01-15 | 2015-11-05 | Novartis Ag | Use of alpha 7 nicotinic acetylcholine receptor agonists |
| ES2883232T3 (es) | 2013-01-15 | 2021-12-07 | Novartis Ag | Uso de agonistas del receptor nicotínico de acetilcolina alfa 7 |
| WO2014111837A1 (en) | 2013-01-15 | 2014-07-24 | Novartis Ag | Use of alpha 7 nicotinic acetylcholine receptor agonists |
| WO2014111751A1 (en) | 2013-01-15 | 2014-07-24 | Novartis Ag | Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy |
| WO2014153424A1 (en) * | 2013-03-19 | 2014-09-25 | La Jolla Institute For Allergy And Immunology | Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins) |
| BR112016021535A8 (pt) | 2014-03-20 | 2021-07-20 | Alkermes Pharma Ireland Ltd | kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso |
| WO2015154064A2 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| CN104288771B (zh) * | 2014-09-30 | 2017-03-15 | 郑州大学第五附属医院 | α7nAChR激动剂的新用途 |
| US10857140B2 (en) | 2015-05-06 | 2020-12-08 | The Regents Of The University Of California | K-Ras modulators |
| US9724340B2 (en) | 2015-07-31 | 2017-08-08 | Attenua, Inc. | Antitussive compositions and methods |
| US10282666B1 (en) | 2015-11-10 | 2019-05-07 | Google Llc | Coherency detection and information management system |
| RU2675111C2 (ru) * | 2017-03-31 | 2018-12-17 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" | Способ стимуляции нейрогенеза в гиппокампе |
| EP3612526A2 (en) | 2017-04-20 | 2020-02-26 | The Regents of the University of California | K-ras modulators |
| AU2019230014B2 (en) | 2018-03-05 | 2024-11-28 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4203990A (en) | 1979-04-30 | 1980-05-20 | G. D. Searle & Co. | Anti-diarrheal 2-substituted quinuclidines |
| DE58906678D1 (de) | 1988-07-28 | 1994-02-24 | Ciba Geigy | Kupfer- und Nickeldihalogenidkomplexe, Verfahren zu deren Herstellung und deren Verwendung. |
| US4922901A (en) | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
| EP0402056A3 (en) | 1989-06-06 | 1991-09-04 | Beecham Group p.l.c. | Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them |
| CA2022886A1 (en) | 1989-08-08 | 1991-02-09 | Raymond Baker | Substituted pyridines, their preparation, formulations and use in dementia |
| IN173570B (enExample) | 1989-11-23 | 1994-06-04 | Pfizer | |
| DK40890D0 (da) | 1990-02-16 | 1990-02-16 | Ferrosan As | Substituerede urinstofforbindelser, deres fremstilling og anvendelse |
| EP0492903A1 (en) | 1990-12-21 | 1992-07-01 | MERCK SHARP & DOHME LTD. | Substituted pyrazines, pyrimidines and pyridazines for use in the treatment of glaucoma |
| EP0573568B1 (en) | 1991-03-01 | 2001-01-24 | University Of Florida Research Foundation, Inc. | Use of nicotinic analogs for treatment of degenerative diseases of the nervous system |
| US5212188A (en) | 1992-03-02 | 1993-05-18 | R. J. Reynolds Tabacco Company | Method for treatment of neurodegenerative diseases |
| US5276043A (en) | 1992-04-10 | 1994-01-04 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5977144A (en) | 1992-08-31 | 1999-11-02 | University Of Florida | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines |
| DE69332641T2 (de) | 1992-08-31 | 2003-11-27 | University Of Florida Research Foundation, Inc. | Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems |
| IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
| US5852041A (en) | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
| IL109451A0 (en) * | 1993-04-29 | 1994-07-31 | Zeneca Ltd | Heterocyclic derivatives |
| WO1995003306A1 (en) | 1993-07-22 | 1995-02-02 | E.I. Du Pont De Nemours And Company | Arthropodicidal azacyclic heterocycles |
| US5493026A (en) | 1993-10-25 | 1996-02-20 | Organix, Inc. | Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders |
| US5510355A (en) | 1994-09-06 | 1996-04-23 | Bencherif; Merouane | Depolarizing skeletal muscle relaxants |
| US5998404A (en) | 1994-10-24 | 1999-12-07 | Eli Lilly And Company | Heterocyclic compounds and their use |
| US5604231A (en) | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
| US5597919A (en) | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
| US5824692A (en) | 1995-01-06 | 1998-10-20 | Lippiello; Patrick Michael | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
| US5616707A (en) | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
| US5859004A (en) | 1995-02-17 | 1999-01-12 | Novo Nordisk A/S | Use of heterocyclic compounds for the treatment of conditions caused by malfunctioning of the nicotinic cholinergic system |
| US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5583140A (en) | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
| JPH11508540A (ja) | 1995-06-29 | 1999-07-27 | ノボ ノルディスク アクティーゼルスカブ | 新規の置換アザ環式またはアザ二環式化合物 |
| AU7083596A (en) | 1995-09-22 | 1997-04-09 | Novo Nordisk A/S | Novel substituted azacyclic or azabicyclic compounds |
| US5712270A (en) | 1995-11-06 | 1998-01-27 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
| US5616716A (en) | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
| SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| US5663356A (en) | 1996-04-23 | 1997-09-02 | Ruecroft; Graham | Method for preparation of aryl substituted alefinic secondary amino compounds |
| US5726189A (en) | 1996-05-03 | 1998-03-10 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes |
| ZA9711092B (en) | 1996-12-11 | 1999-07-22 | Smithkline Beecham Corp | Novel compounds. |
| US5811442A (en) | 1997-02-21 | 1998-09-22 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow |
| US5861423A (en) | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| HUP0002713A3 (en) | 1997-05-30 | 2001-02-28 | Neurosearch As | 8-azabicyclo[3,2,1]oct-2-ene and octane derivatives, process for preparation thereof, pharmaceutical compositions comprising thereof and their use |
| AR013184A1 (es) | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
| DE69907894T2 (de) | 1998-04-02 | 2004-03-11 | Targacept, Inc. | Azatricyclo[3.3.1.1]decanderivate und diese enthaltende phrmazeutische zubereitungen |
| US5952339A (en) | 1998-04-02 | 1999-09-14 | Bencherif; Merouane | Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release |
| DK1083889T3 (da) | 1998-06-01 | 2004-04-13 | Ortho Mcneil Pharm Inc | Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme |
| US6310043B1 (en) | 1998-08-07 | 2001-10-30 | Governors Of The University Of Alberta | Treatment of bacterial infections |
| GB9821503D0 (en) | 1998-10-02 | 1998-11-25 | Novartis Ag | Organic compounds |
| US6432975B1 (en) | 1998-12-11 | 2002-08-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| US6734215B2 (en) | 1998-12-16 | 2004-05-11 | University Of South Florida | Exo-S-mecamylamine formulation and use in treatment |
| SE9900100D0 (sv) | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
| FR2791678B1 (fr) * | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique |
| SE9904176D0 (sv) * | 1999-11-18 | 1999-11-18 | Astra Ab | New use |
| SE0000540D0 (sv) | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
| GB0010955D0 (en) | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
| EA005520B1 (ru) | 2000-06-27 | 2005-04-28 | Лабораториос С.А.Л.В.А.Т.,С.А. | Карбаматы, полученные из арилалкиламинов |
| US6492386B2 (en) | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| EP1381603A2 (en) | 2000-08-18 | 2004-01-21 | PHARMACIA & UPJOHN COMPANY | Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands ) |
| WO2002016357A2 (en) | 2000-08-18 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
| WO2002015662A2 (en) | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists |
| US6500840B2 (en) | 2000-08-21 | 2002-12-31 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| JP2004506734A (ja) | 2000-08-21 | 2004-03-04 | ファルマシア・アンド・アップジョン・カンパニー | 疾患治療用のキヌクリド置換ヘテロアリール部分 |
| KR100869722B1 (ko) | 2000-12-22 | 2008-11-21 | 알미랄 에이쥐 | 퀴누클리딘 카르바메이트 유도체 및 ｍ3 길항제로서 그의사용 |
| US20020086871A1 (en) * | 2000-12-29 | 2002-07-04 | O'neill Brian Thomas | Pharmaceutical composition for the treatment of CNS and other disorders |
| EP1397366B1 (en) | 2001-06-01 | 2007-02-07 | AstraZeneca AB | Novel ligand for nicotinic acetylcholine receptors useful in therapy |
| US6569865B2 (en) | 2001-06-01 | 2003-05-27 | Astrazeneca Ab | Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine |
| AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
| WO2003011837A1 (en) | 2001-08-01 | 2003-02-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| BR0212123A (pt) | 2001-08-24 | 2004-07-20 | Upjohn Co | 7-aza[2.2.1]biciclo-heptanos substituìdos com arila para o tratamento de doenças |
| US6562816B2 (en) | 2001-08-24 | 2003-05-13 | Pharmacia & Upjohn Company | Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease |
| WO2003022856A1 (en) | 2001-09-12 | 2003-03-20 | Pharmacia & Upjohn Company | Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases |
| JP2005523288A (ja) | 2002-02-19 | 2005-08-04 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド |
| WO2003072578A1 (en) | 2002-02-20 | 2003-09-04 | Pharmacia & Upjohn Company | Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity |
| ES2348282T3 (es) * | 2002-04-18 | 2010-12-02 | Astrazeneca Ab | Compuestos de tienilo. |
| BR0309345A (pt) | 2002-04-18 | 2005-02-15 | Astrazeneca Ab | Composto ou sais farmaceuticamente aceitáveis do mesmo, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, de distúrbios psicóticos ou de distúrbios de dano intelectual, e de jetlag, interrupção do hábito de fumar, dependência de nicotina, ânsias, dor e colite ulcerativa |
| MXPA04010191A (es) | 2002-04-18 | 2005-02-03 | Astrazeneca Ab | Compuestos de furilo. |
| JP2005537297A (ja) | 2002-08-01 | 2005-12-08 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | アルファ−７ｎａｃｈｒ活性を有する１ｈ−ピラゾールおよび１ｈ−ピロール−アザビシクロ化合物 |
| SE0202465D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New compounds |
| SE0202430D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New Compounds |
| PL375533A1 (en) | 2002-08-14 | 2005-11-28 | Neurosearch A/S | Novel quinuclidine derivatives and their use |
| EP2305664A1 (en) | 2002-08-30 | 2011-04-06 | Memory Pharmaceuticals Corporation | Anabaseine derivatives useful in the treatment of neurodegeneratives diseases |
| CA2499128C (en) | 2002-09-25 | 2012-07-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| WO2004039366A1 (en) | 2002-11-01 | 2004-05-13 | Pharmacia & Upjohn Company Llc | Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
| CA2503786A1 (en) | 2002-11-01 | 2004-05-13 | Pharmacia & Upjohn Company Llc | Compounds having both alpha7 nicotinic agonist activity and 5ht, antagonist activity for treatment of cns diseases |
| JP4750421B2 (ja) | 2002-12-06 | 2011-08-17 | ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト | α７受容体結合コリン作動性アゴニストを用いる炎症の阻害 |
| JP2006510662A (ja) | 2002-12-11 | 2006-03-30 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | α７ニコチン性アセチルコリン受容体アゴニストとその他の化合物との組合せによる疾患の治療 |
| EP1572300A1 (en) | 2002-12-11 | 2005-09-14 | Pharmacia & Upjohn Company LLC | Combination for the treatment of adhd |
| US6917746B2 (en) | 2002-12-17 | 2005-07-12 | 3M Innovative Properties Company | Apparatus and method for creating a fiber optic circuit |
| US6777617B2 (en) | 2002-12-30 | 2004-08-17 | 3M Innovative Properties Company | Telecommunications terminal |
| ATE445618T1 (de) | 2003-02-27 | 2009-10-15 | Neurosearch As | Neue diazabicyclische arylderivate |
| AU2004255920B2 (en) | 2003-07-08 | 2008-05-15 | Astrazeneca Ab | Spiro [1-azabicyclo [2.2.2] octan-3,5'-oxazolidin]-2'-one derivatives with affinity to the alpha7 nicotinic acetylcholine receptor |
| BRPI0414633A (pt) | 2003-09-25 | 2006-11-07 | Astrazeneca Ab | composto, composição de diagnóstico, método para a doagnose de doenças ou condições, e, kit |
| EP1678183A1 (en) | 2003-10-21 | 2006-07-12 | AstraZeneca AB | Spirofuropyridine aryl derivatives |
| US20050137217A1 (en) | 2003-12-22 | 2005-06-23 | Jianguo Ji | Spirocyclic quinuclidinic ether derivatives |
| US20050245531A1 (en) | 2003-12-22 | 2005-11-03 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| US20050137398A1 (en) | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-Quinuclidinyl heteroatom bridged biaryl derivatives |
| US7160876B2 (en) | 2003-12-22 | 2007-01-09 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| US20050137203A1 (en) | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-quinuclidinyl amino-substituted biaryl derivatives |
| CA2555311A1 (en) * | 2004-02-04 | 2005-08-18 | Neurosearch A/S | Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands |
| CA2567977A1 (en) | 2004-04-22 | 2006-01-05 | Memory Pharmaceutical Corporation | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof |
| KR20070015607A (ko) | 2004-05-07 | 2007-02-05 | 메모리 파마슈티칼스 코포레이션 | 1ｈ-인다졸, 벤조티아졸, 1,2-벤조이속사졸,1,2-벤조이소티아졸, 및 크로몬 및 그의 제조법 및 용도 |
| MX2007004269A (es) * | 2004-10-20 | 2007-06-15 | Neurosearch As | Derivados de arilo diazabiciclico nuevos y su uso medico. |
| EP1831231A1 (en) | 2004-12-15 | 2007-09-12 | AstraZeneca AB | Nicotinic acetylcholine receptor ligands |
| WO2006069097A2 (en) * | 2004-12-22 | 2006-06-29 | Memory Pharmaceuticals Corporation | Nicotinic alpha-7 receptor ligands and preparation and uses thereof |
| CA2610795C (en) | 2005-06-07 | 2015-01-06 | University Of Florida Research Foundation, Inc. | 3-arylidene-anabaseine compounds as alpha 7 nicotitnic receptor selective ligands |
| WO2007024814A1 (en) * | 2005-08-22 | 2007-03-01 | Targacept, Inc. | HETEROARYL-SUBSTiTUTED DIAZATRICYCLOALKANES, METHODS FOR ITS PREPARATION AND USE THEREOF |
| WO2007038367A1 (en) | 2005-09-23 | 2007-04-05 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| US8316104B2 (en) * | 2005-11-15 | 2012-11-20 | California Institute Of Technology | Method and apparatus for collaborative system |
| SA08290475B1 (ar) * | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| EP2633868A1 (en) * | 2008-02-13 | 2013-09-04 | Targacept, Inc. | Combination of alpha 7 nicotinic agonists and antipsychotics |
-
2008
- 2008-07-03 SA SA08290475A patent/SA08290475B1/ar unknown
- 2008-07-31 TW TW102135271A patent/TW201402116A/zh unknown
- 2008-07-31 TW TW097129030A patent/TWI429435B/zh not_active IP Right Cessation
- 2008-07-31 TW TW102135272A patent/TW201402117A/zh unknown
- 2008-08-01 CL CL2008002271A patent/CL2008002271A1/es unknown
- 2008-08-01 DK DK08782584.0T patent/DK2182949T3/da active
- 2008-08-01 PL PL08782584T patent/PL2182949T3/pl unknown
- 2008-08-01 AU AU2008283813A patent/AU2008283813A1/en not_active Abandoned
- 2008-08-01 HU HUE11194142A patent/HUE030387T2/en unknown
- 2008-08-01 WO PCT/US2008/071872 patent/WO2009018505A1/en not_active Ceased
- 2008-08-01 SA SA112330303A patent/SA112330303B1/ar unknown
- 2008-08-01 PE PE2012000920A patent/PE20121820A1/es not_active Application Discontinuation
- 2008-08-01 CN CN200880101593A patent/CN101868237A/zh active Pending
- 2008-08-01 JP JP2010520219A patent/JP2010535252A/ja active Pending
- 2008-08-01 EP EP11194161.3A patent/EP2465501B1/en active Active
- 2008-08-01 JP JP2010520213A patent/JP5358573B2/ja active Active
- 2008-08-01 AU AU2008283807A patent/AU2008283807B2/en not_active Ceased
- 2008-08-01 CN CN201611140124.5A patent/CN106831755A/zh active Pending
- 2008-08-01 EP EP08782589A patent/EP2185152A2/en not_active Withdrawn
- 2008-08-01 US US12/674,327 patent/US20110124678A1/en not_active Abandoned
- 2008-08-01 WO PCT/US2008/071893 patent/WO2009018511A2/en not_active Ceased
- 2008-08-01 PH PH1/2012/501513A patent/PH12012501513A1/en unknown
- 2008-08-01 ES ES11194161.3T patent/ES2606752T3/es active Active
- 2008-08-01 EP EP12164661A patent/EP2484363A1/en not_active Withdrawn
- 2008-08-01 SI SI200830931T patent/SI2182949T1/sl unknown
- 2008-08-01 DK DK11194142.3T patent/DK2431037T3/en active
- 2008-08-01 CA CA2694510A patent/CA2694510A1/en not_active Abandoned
- 2008-08-01 MX MX2010001293A patent/MX2010001293A/es not_active Application Discontinuation
- 2008-08-01 BR BRPI0814889A patent/BRPI0814889A2/pt not_active IP Right Cessation
- 2008-08-01 MX MX2012009257A patent/MX346451B/es unknown
- 2008-08-01 AR ARP080103348A patent/AR067775A1/es not_active Application Discontinuation
- 2008-08-01 MX MX2012009258A patent/MX346748B/es unknown
- 2008-08-01 KR KR1020107004216A patent/KR20100051684A/ko not_active Ceased
- 2008-08-01 PE PE2012000921A patent/PE20121821A1/es not_active Application Discontinuation
- 2008-08-01 MY MYPI2010000501A patent/MY148002A/en unknown
- 2008-08-01 EP EP11194142.3A patent/EP2431037B1/en active Active
- 2008-08-01 HR HRP20130286AT patent/HRP20130286T1/hr unknown
- 2008-08-01 NZ NZ582828A patent/NZ582828A/en not_active IP Right Cessation
- 2008-08-01 KR KR1020107004202A patent/KR20100063043A/ko not_active Withdrawn
- 2008-08-01 RS RS20130115A patent/RS52743B/sr unknown
- 2008-08-01 CA CA2694504A patent/CA2694504C/en not_active Expired - Fee Related
- 2008-08-01 US US12/184,312 patent/US7981906B2/en active Active
- 2008-08-01 EP EP08782584A patent/EP2182949B1/en active Active
- 2008-08-01 CN CN2013100489009A patent/CN103172628A/zh active Pending
- 2008-08-01 ME MEP-2013-28A patent/ME01508B/me unknown
- 2008-08-01 ES ES11194142.3T patent/ES2611139T3/es active Active
- 2008-08-01 NZ NZ582986A patent/NZ582986A/en not_active IP Right Cessation
- 2008-08-01 BR BRPI0815009-5A2A patent/BRPI0815009A2/pt not_active IP Right Cessation
- 2008-08-01 PT PT87825840T patent/PT2182949E/pt unknown
- 2008-08-01 PE PE2008001292A patent/PE20090566A1/es not_active Application Discontinuation
- 2008-08-01 PH PH1/2012/501514A patent/PH12012501514A1/en unknown
- 2008-08-01 UY UY0001031265A patent/UY31265A/es not_active Application Discontinuation
- 2008-08-01 ES ES08782584T patent/ES2415107T3/es active Active
- 2008-08-01 CN CN200880103971.1A patent/CN101784273B/zh not_active Expired - Fee Related
- 2008-08-01 EP EP11075209A patent/EP2409703A1/en not_active Withdrawn
-
2010
- 2010-01-18 NO NO20100077A patent/NO20100077L/no not_active Application Discontinuation
- 2010-01-18 NO NO20100078A patent/NO20100078L/no not_active Application Discontinuation
- 2010-01-29 ZA ZA2010/00719A patent/ZA201000719B/en unknown
- 2010-03-02 CO CO10024579A patent/CO6260080A2/es not_active Application Discontinuation
- 2010-03-02 EC EC2010010008A patent/ECSP10010008A/es unknown
- 2010-03-02 EC EC2010010007A patent/ECSP10010007A/es unknown
- 2010-03-02 CO CO10024587A patent/CO6260081A2/es not_active Application Discontinuation
-
2011
- 2011-05-26 US US13/116,080 patent/US8541446B2/en active Active
- 2011-05-26 US US13/116,163 patent/US8119659B2/en active Active
-
2012
- 2012-04-02 IL IL218976A patent/IL218976A0/en not_active IP Right Cessation
- 2012-06-04 AU AU2012203288A patent/AU2012203288B2/en not_active Ceased
- 2012-09-19 RU RU2012140148/15A patent/RU2012140148A/ru not_active Application Discontinuation
- 2012-09-19 RU RU2012140182/15A patent/RU2012140182A/ru not_active Application Discontinuation
-
2013
- 2013-01-30 CY CY20131100081T patent/CY1113561T1/el unknown
- 2013-07-17 JP JP2013148087A patent/JP5852611B2/ja active Active
- 2013-07-17 JP JP2013148091A patent/JP6106549B2/ja active Active
- 2013-07-22 US US13/947,157 patent/US8846715B2/en active Active
- 2013-08-02 CL CL2013002227A patent/CL2013002227A1/es unknown
- 2013-08-02 CL CL2013002226A patent/CL2013002226A1/es unknown
-
2014
- 2014-08-25 US US14/467,289 patent/US20150045386A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1113561T1 (el) | (2s,3r)-ν-(2-((3-πυριδινυλ)μεθυλ)-1-αζαδικυκλο[2.2.2]οκτ-3-υλ)βενζοφουραν-2-καρβοξαμιδιο, νεες μορφες αλατων και μεθοδοι χρησεως αυτων | |
| EA201170976A1 (ru) | Получение и виды терапевтического применения (2s,3r)-n-2-((3-пиридинил)метил)-1-азабицикло[2.2.2]окт-3-ил)-3,5-дифторбензамида | |
| MX2010002732A (es) | Inhibidores de f1f0-atpasa y metodos relacionados. | |
| JO3346B1 (ar) | مواد مضادة C5aR | |
| CY1118452T1 (el) | Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης | |
| EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
| EA201001159A1 (ru) | Конденсированные гетероциклические производные и их применение | |
| CY1112083T1 (el) | Υποκαθιστουμενα ν-φαινυλο-διπυρρολιδινο καρβοξαμιδια και η θεραπευτικη τους χρηση | |
| ATE540944T1 (de) | Pyridylpiperidinorexin-rezeptorantagonisten | |
| EA200900831A1 (ru) | Модуляторы никотиновых ацетилхолиновых рецепторов | |
| UA109916C2 (uk) | 2-аміно-4-арилтіазольні сполуки як антагоністи trра1 | |
| MX346186B (es) | Inhibidores de proteina cinasas. | |
| MX355142B (es) | Acetamidas heterociclicas sustituidas como agonistas del receptor opioide kappa (kor). | |
| CY1112683T1 (el) | Υποκατεστημενες καρβοξαμιδες ν-φαινυλ-διπυρρολιδινης και θεραπευτικες χρησεις τους | |
| EA200800660A1 (ru) | Тетрагидрохинолиноны и их применение в качестве модуляторов метаботропных глутаматных рецепторов | |
| CY1119800T1 (el) | Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων | |
| MX2010004003A (es) | N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas. | |
| MA32943B1 (fr) | Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique | |
| NO20074332L (no) | Fremgangsmate og preparat for behandling av sentralnervesystemforstyrrelser | |
| BRPI0508051A (pt) | derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes | |
| SE0401465D0 (sv) | New substituted piperdines as modulators of dopamine neurotransmission | |
| DE602004010314D1 (de) | Behandlung von neurodegenerativen erkrankungen durch verwendung von degs-inhibitoren | |
| SE0502254L (sv) | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission | |
| EA201001828A1 (ru) | Способ синтеза производных 3,6-дигидро-1,3,5-триазина | |
| EA201270610A1 (ru) | Хинуклидиновые соединения как альфа-7 лиганды ацетилхолинового рецептора |